Trial Design: Phase I study to evaluate safety and anti-tumor activity of autologous T cells with alpha-feto protein (AFP(c332T)) receptor in patients with advanced hepatocellular carcinoma (HCC)

导出原文传递

翻译打印收藏纠错

作者： Finn, Richard S. ^[1] ; Feun, Lynn ^[2] ; Kelley, Robin K. ^[3] ; Norry, Elliot ^[4] ; Ranganathan, Sulabha ; Gerry, Andrew B. ; Maroto, Miguel ; Amado, Rafael G.

作者单位： Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA ^[1] Adaptimmune, Philadelphia, PA USA ^[2] Sylvester Comprehens Canc Ctr, Miami, FL USA ^[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA ^[4]

发布时间 2020-08-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Hepatology

2017年66卷Suppl.1期

723A-723A页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Trial Design: Phase I study to evaluate safety and anti-tumor activity of autologous T cells with alpha-feto protein (AFP(c332T)) receptor in patients with advanced hepatocellular carcinoma (HCC)

Hepatology

相似文献

Hepatology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Trial Design: Phase I study to evaluate safety and anti-tumor activity of autologous T cells with alpha-feto protein (AFP(c332T)) receptor in patients with advanced hepatocellular carcinoma (HCC)

Hepatology

相似文献

Hepatology

相关期刊

检索历史清除